Navigation Links
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
Date:7/2/2009

d formulation of donepezil, are currently being conducted by Teikoku Pharma USA, Inc. in the United States. An NDA submission to the U.S. FDA is planned for the middle of fiscal year 2009 based on the results of the clinical trials. Eisai is working on this new formulation of donepezil based on agreements with Teikoku Seiyaku Co., Ltd. and its U.S. subsidiary, Teikoku Pharma USA, Inc.

About Aricept

Aricept is the first and only prescription medication approved by the U.S. Food and Drug Administration for mild, moderate and severe dementia of the Alzheimer's type. This indication is supported by evidence-based medicine backed by numerous well-controlled clinical studies of AD in all stages and settings among thousands of patients that demonstrated that Aricept improves cognition and delays functional decline.

Aricept is well tolerated, but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse. Some people who take Aricept may experience fainting. Some people may have nausea, vomiting, diarrhea, bruising, or not sleep well. Some people may have muscle cramps or loss of appetite or may feel tired. In studies these were usually mild and temporary.

For more information about managing AD, about Aricept, and for full prescribing information, call 1-888-274-2378 or visit www.aricept.com. Aricept is co-promoted by Eisai Inc. and Pfizer Inc.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide hea
'/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
4. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
5. Angiomax Will Retain Decision Resources Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
6. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
7. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
8. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
9. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
10. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in ... announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products ... Society (NASS) 2009 Annual Meeting, taking place November 10th through ... been used in 40 spinal surgeries in the ...
... Inc. (Nasdaq: VVUS ) today announced that Timothy Morris, chief ... Lazard Capital Markets 6th Annual Healthcare Conference. , The VIVUS presentation ... on Wednesday, November 18, 2009 at 1:45 p.m. ET. A ... at http://ir.vivus.com . , About VIVUS ...
Cached Medicine Technology:Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 2Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 3Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 4Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 5VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:8/31/2015)... , ... August 31, 2015 , ... ... introduces the Talent Management Division , a department devoted to helping organizations ... department. Talent management goes beyond selection, and The Brooks Group believes in offering ...
(Date:8/31/2015)... ... 2015 , ... According to book reviewer Angie Santangeloon , Dr. ... Cancer is an excellent resource for everyone since one in three persons will ... in explaining what cancer is in a easy to understand medically accurate way. The ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... excited to establish its first Digital Hub in North America, now open in ... selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and beautiful ...
(Date:8/31/2015)... CO (PRWEB) , ... August 31, 2015 , ... Adult ... potential Denver area dermatology patients of the treatments and services available to ... patients by utilizing an innovative and ‘responsive design’ that allows visitors to view the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... TheHardwareCity.com is pleased ... tools set . , These home repair tool sets are manufactured by Allied Tools. ... around the house. The tri-fold tool set allows yard and house work to be ...
Breaking Medicine News(10 mins):Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2
... , NANJING, China, June 19 ... a leading manufacturer and supplier of branded generic and,innovative ... annual,report on Form 20-F for the year ended December ... 18, 2009. The annual report can be accessed on,the ...
... ... will be introducing ten (10) new products at the 26th Annual ASMBS scheduled for June ... ... introducing ten (10) new products at the 26th Annual ASMBS scheduled for June 21-26 in ...
... Georgia facility to offer new choice in cancer treatment with fully ... 18 Cancer Treatment Centers of America (CTCA) announced today that ... cancer treatment hospital that will serve patients in the Southeast and ... View the Multimedia News Release, go to: http://www.prnewswire.com/mnr/cancercenter/38837 ...
... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
... , Senator John D. Rockefeller IV and Senator Bob Corker ... YORK, June 18 The American Society of Interventional ... All Schedules Prescription Electronic Reporting (NASPER) Act has received ... Virginia and Senator Bob Corker of Tennessee. , ...
... (Nasdaq: MEDQ ) has announced it has added ... Chief Information Officer. , , "As CIO, ... and development resources are aligned with its strategic and operational ... for profitable revenue and market share growth," says Peter Masanotti, ...
Cached Medicine News:Health News:Bariatric Advantage to Introduce Ten (10) New Products at ASMBS 2Health News:VIDEO: Cancer Treatment Centers of America Selects Site in GA for Proposed Hospital Serving Patients in Southeast 2Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 3Health News:MedQuist Adds Kevin Piltz as New Chief Information Officer 2
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... is as easy as 1-2-3: just three simple ... satisfaction with rapid information before they leave your ... with the appropriate therapy; no more follow-up appointments ... Strep A Test is a rapid immunochromatographic assay ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: